Literature DB >> 7132061

Absorption and disposition of furosemide in congestive heart failure.

D C Brater, R Seiwell, S Anderson, A Burdette, G J Dehmer, P Chennavasin.   

Abstract

Changes in response to furosemide and other diuretics in patients with congestive heart failure (CHF) could occur because of disease-induced changes in absorption of the drug or changes in disposition which affect its access to its site of action. A difference was not found in the bioavailability of forosemide in patients with CHF compared to normal volunteers, 31 +/- 12 vs. 38 +/- 20% (mean +/- sd), respectively. Both groups showed considerable interindividual variability, though serial analyses within individuals revealed consistency. Amounts of furosemide delivered into the urine after an intravenous dose correlated significantly to that after an oral dose implying that the interindividual variability is not caused primarily by variability in absorption in either group. Overall, disposition kinetics of furosemide did not differ between groups. Because of heterogeneity of renal and cardiac function among the patients, we were able to demonstrate correlations of plasma and renal clearance of furosemide with renal function; in turn, renal function correlated with left ventricular ejection fraction. Consequently, some patients had changes in furosemide disposition, but, for the most part, differences in response to furosemide were caused by abnormal responses to, rather than changed handling of the diuretic.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7132061     DOI: 10.1038/ki.1982.149

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

Review 1.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 2.  Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).

Authors:  L L Ponto; R D Schoenwald
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

Review 3.  Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships.

Authors:  D A Sica; T W Gehr
Journal:  Clin Pharmacokinet       Date:  1996-03       Impact factor: 6.447

Review 4.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

Review 5.  Resistance to loop diuretics. Why it happens and what to do about it.

Authors:  D C Brater
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

Review 6.  A perspective on diuretic resistance in chronic congestive heart failure.

Authors:  Niel Shah; Raef Madanieh; Mehmet Alkan; Muhammad U Dogar; Constantine E Kosmas; Timothy J Vittorio
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-07-20

7.  Sublingual administration of furosemide: new application of an old drug.

Authors:  Laurent Haegeli; Hans Peter Brunner-La Rocca; Markus Wenk; Matthias Pfisterer; Jürgen Drewe; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2007-09-13       Impact factor: 4.335

8.  Diuretic activity of torasemide and furosemide in chronic heart failure: a comparative double blind cross-over study.

Authors:  A J Scheen; J C Vancrombreucq; J Delarge; A S Luyckx
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism.

Authors:  M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

Review 10.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 1, drugs administered intravenously).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.